Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study

PURPOSE: Omalizumab was first approved in China in 2017 for the treatment of moderate to severe allergic asthma for adult and adolescent patients aged ≥12 years. In accordance with the Chinese Health Authority requirement, the post-authorization safety study (PASS) was conducted to evaluate the safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Nan, Zhi, Lili, Liu, Fengxia, Wang, Yongsheng, Zhang, Qingling, Liu, Xiansheng, Wang, Xueyan, Hao, Guodong, Zhang, Xiuqin, Hu, Qiang, Ligueros-Saylan, Monica, Uddin, Alkaz, Yang, Jing, Liang, Tiantian, Ding, Liju, Li, Runqin, Wang, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289103/
https://www.ncbi.nlm.nih.gov/pubmed/37360967
http://dx.doi.org/10.2147/JAA.S406628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289103/
https://www.ncbi.nlm.nih.gov/pubmed/37360967
http://dx.doi.org/10.2147/JAA.S406628

Ejemplares similares